A retrospective study on the prevalence of anti-phospholipid antibodies, thrombotic events and cutaneous signs of vasculopathy in 173 hospitalized COVID-19 patients
CONCLUSIONS: Anti-phospholipid antibodies cannot be considered responsible for hypercoagulability and thrombotic events in COVID-19 patients. In COVID-19 patients, livedo reticularis and acrocyanosis do not appear to be cutaneous manifestations of APS.PMID:34541915 | DOI:10.1177/20587384211042115
Source: International Journal of Immunopathology and Pharmacology - Category: Allergy & Immunology Authors: Giulia Gasparini Paola Canepa Simonetta Verdiani Luca Carmisciano Emanuele Cozzani Denise De Grazia Orsi Andrea Giancarlo Icardi Aurora Parodi Source Type: research
More News: Allergy & Immunology | Cardiology | Celiac Disease | Coeliac Disease | COVID-19 | Dermatology | Drugs & Pharmacology | Heart | Pulmonary Thromboembolism | Skin | Study | Thrombosis